Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation (CONNECT)

January 30, 2024 updated by: Steffani Bailey, OHSU Knight Cancer Institute

CONNECT: COmpreheNsive TraiNing and Engagement in Cessation Treatment

This phase IV clinical trial determines the impact of implementing a Quitline electronic (e)Referral system with an enhanced academic detailing implementation strategy on Quitline reach, smoking cessation assistance and self-reported quit rates among patients in community health centers. It also examines the cost-effectiveness of Quitline eReferrals both with and without enhanced academic detailing. If this implementation strategy is effective, this strategy could be used to increase smoking cessation treatment through the collaboration between state Quitlines and community health centers that serve large numbers of socioeconomically disadvantaged smokers.

Study Overview

Detailed Description

PRIMARY OBJECTIVES:

I. Implement a Quitline electronic (e)Referral system with enhanced academic detailing (AD) (intervention; n=10 community health centers [CHCs]) and without enhanced AD (comparison; n=10 CHCs) to compare rates of eReferral offers, eReferral acceptance, Quitline enrollment, orders for smoking cessation medication, and receipt of in-clinic counseling among patients identified as current smokers.

II. Assess the effectiveness of implementing a Quitline eReferral system with enhanced AD (intervention) versus without enhanced AD (comparison) on self-reported smoking quit rates among all patients identified as current smokers using electronic health record (EHR) data.

III. Estimate the total annual costs and incremental cost-effectiveness of a Quitline eReferral system, with and without enhanced AD.

OUTLINE: Clinics are randomized to 1 of 2 arms.

ARM I: Clinics are notified via email that the eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding electronic health record (EHR) screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.

ARM II: Clinics receive standard online materials and access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the Quitline eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.

Study Type

Interventional

Enrollment (Estimated)

10000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oregon
      • Portland, Oregon, United States, 97239
        • OHSU Knight Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Study Clinic Inclusion Criteria:

  • In Oregon
  • On the OCHIN Epic EHR for >= 1 year
  • Willing to be randomized to the intervention or comparison condition
  • Willing to recruit a provider to serve as a clinic champion (to share monthly performance audit and feedback at all-staff meetings, determine desired content of booster sessions with clinic team members, and complete a survey at the completion of the intervention period) and a clinic manager to coordinate training and booster sessions

Study Patient Inclusion Criteria:

  • Adult patients (>= 18 years of age)
  • Identified as current tobacco users during >= 1 ambulatory and/or telehealth visit to one of the eligible study clinics over the 24-month study period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm I (Quitline eReferral)
Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.
Receive overview of Quitline services and use of Quitline eReferral via online materials
Experimental: ARM II (Quitline eReferral plus enhanced AD)
Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.
Receive overview of Quitline services and use of Quitline eReferral via online materials
  • Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation
  • Follow-up booster sessions
  • Monthly performance audit and feedback
Other Names:
  • EAD

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accepted electronic (e)Referral to Quitline
Time Frame: At any point during the 24-month intervention period
Proportion of patients who were offered and accepted the Quitline eReferral in intervention (EAD) versus comparator clinics. Will use a logistic mixed effects model that addresses the following design features of the study: 1) will include random intercepts for providers and clinic to account for clustering of patients within providers within clinics; 2) will perform an intent-to-treat analysis; 3) hypothesis tests will be two-sided.
At any point during the 24-month intervention period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quitline eReferral offered
Time Frame: At any point during the 24-month intervention period
Proportion of patients who were offered the Quitline eReferral in intervention (EAD) versus comparator clinics. Will construct similar logistic mixed effects models.
At any point during the 24-month intervention period
Quitline enrollment
Time Frame: At any point during the 24-month intervention period
Proportion of patients who were offered the Quitline eReferral and enrolled in Quitline services in intervention (EAD) versus comparator clinics. Will construct similar logistic mixed effects models.
At any point during the 24-month intervention period
Receipt of in-office counseling
Time Frame: At any point during the 24-month intervention period
Proportion of patients with an indication in the electronic health record (EHR) of receipt of counseling during an office visit in intervention (EAD) versus comparator clinics. Will construct similar logistic mixed effects models.
At any point during the 24-month intervention period
Smoking cessation medication ordered
Time Frame: At any point during the 24-month intervention period
Proportion of patients with a smoking cessation medication in the 'medication orders' list of the EHR in intervention (EAD) versus comparator clinics. Will construct similar logistic mixed effects models.
At any point during the 24-month intervention period
Smoking cessation
Time Frame: At any point during the 24-month intervention period or up to 6 months post-intervention
Proportion of patients with EHR status change from current to former smoker. Will utilize similar generalized linear mixed model (GLMM) modeling to estimate the impact of the intervention on cessation outcomes.
At any point during the 24-month intervention period or up to 6 months post-intervention
Annual intervention costs
Time Frame: Years 1-4
Mean total annual costs in years 1-4 to implement the eReferral into the EHR and maintain eReferral system, with and without enhanced academic detailing.
Years 1-4
Cost-effectiveness
Time Frame: Years 1-4
Mean total annual costs over years 1-4 by study arm, overall and for patients enrolled in the Quitline.
Years 1-4
Incremental cost-effectiveness ratio
Time Frame: Years 1-4
Difference in total costs by study arm, overall and for patients enrolled in Quitline.
Years 1-4

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tobacco use assessed
Time Frame: At any point during the 24-month intervention period
Proportion of patients who had a current tobacco use assessment in intervention (EAD) versus comparator clinics.
At any point during the 24-month intervention period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Steffani Bailey, OHSU Department of Family Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2023

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

March 31, 2026

Study Registration Dates

First Submitted

July 9, 2021

First Submitted That Met QC Criteria

July 9, 2021

First Posted (Actual)

July 21, 2021

Study Record Updates

Last Update Posted (Actual)

February 1, 2024

Last Update Submitted That Met QC Criteria

January 30, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY00023019 (OHSU Knight Cancer Institute)
  • NCI-2021-06581 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • R01CA255016 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Smoking Cessation

Clinical Trials on Informational Intervention

3
Subscribe